ReviewFrontiers in endocrinology2025
Application progress of artificial intelligence in managing thyroid disease.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Artificial intelligence in the diagnosis of thyroid diseases: applications and challenges.Frontiers in radiology · 2026Review
- Review
- Molecular Diagnostics and Personalized Therapeutics in Differentiated Thyroid Carcinoma: A Clinically Oriented Review.Diagnostics (Basel, Switzerland) · 2025Review
- Humanizing pulmonary care in the era of acoustic artificial intelligence: toward global health equity.Frontiers in medicine · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) has been used to study thyroid diseases since the 1990s. Previously, it mainly concentrated on the diagnosis of thyroid function and distinguishing benign from malignant thyroid nodules. With the rapid development of machine and deep learning, AI has been widely used in multiple areas of thyroid disease management, including image analysis, pathological diagnosis, personalized treatment, patient monitoring, and follow-up. This review systematically examines the evolution of AI applications in thyroid disease management since the 1990s, with a focus on diagnostic innovations, therapeutic personalization, and emerging challenges in clinical implementation. AI not only reduces the subjectivity associated with ultrasound examinations but also enhances the differentiation rate of benign and malignant thyroid nodules, thereby reducing the frequency of unnecessary fine-needle aspirations. AI synthesizes multimodal data, such as ultrasound, electronic health records, and wearable sensors, for continuous health monitoring. This integration facilitates the early detection of subclinical recurrence risk, particularly in patients who have undergone thyroidectomy. Despite the broad prospects of AI applications, challenges related to data privacy, model interpretability, and clinical applicability remain. This review critically evaluates studies across the ultrasound, CT/MRI, and histopathology domains, while addressing barriers to clinical translation, such as data heterogeneity and ethical concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.